Please assess the completion status of the following clinical trial:

Trial Title: Vascular Dysfunction in Black Individuals: Roles of Nitric Oxide and Endothelin-1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Self-identification of their race and the race of their biological parents as being only Black (i.e., African American) or only White (i.e., Caucasian American)~* Born and raised in the United States~Exclusion Criteria:~* Mixed races~* Any chronic or ongoing disease~* Prescribed pharmacological treatment~* Smoking or tobacco use~* Obesity (body mass index \> 30 kg / m2)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Beetroot juice (Aim 1a) (Type: ACTIVE_COMPARATOR): Upon arriving at the laboratory, participants will ingest 140 ml of beetroot juice containing a high (\~12.8 mmol) concentration of nitrates (James White Drinks, Suffolk, UK).
- Placebo (Aim 1a) (Type: PLACEBO_COMPARATOR): Upon arriving at the laboratory, participants will ingest 140 ml of beetroot juice containing a low concentration (\~0.0055 mmol) of nitrates (James White Drinks, Suffolk, UK).
- L-citrulline (Aim 1b) (Type: ACTIVE_COMPARATOR): Participants will receive pills containing 3 g of L-citrulline (Superior Labs, Park City, UT) to take twice daily for 7 days before the study visit.
- Placebo (Aim 1b) (Type: PLACEBO_COMPARATOR): Participants will receive pills containing a placebo to take twice daily for 7 days before the study visit.
- Sildenafil (Aim 1c) (Type: ACTIVE_COMPARATOR): Upon arriving at the laboratory, participants will ingest a liquid mixture containing Sildenafil (100 mg), an inhibitor of phosphodiesterase 5.
- Placebo (Aim 1c) (Type: PLACEBO_COMPARATOR): Upon arriving at the laboratory, participants will ingest a liquid mixture containing a placebo.
- Bosentan (Aim 2) (Type: ACTIVE_COMPARATOR): Upon arriving at the laboratory, participants will ingest a liquid mixture containing Bosentan (125 mg), a non-selective blocker of endothelin-1 receptors ETA and ETB.
- Placebo (Aim 2) (Type: PLACEBO_COMPARATOR): Upon arriving at the laboratory, participants will ingest a liquid mixture containing a placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).